Qiagen scales its way up the IVD ladder through strategic acquisitions
This article was originally published in Clinica
Diagnostics clearly is the market to invest in. The last few years have seen companies with a mainly research-oriented customer base buying in more clinically-relevant companies. Invitrogen, for example, acquired Applied Biosystems last year and now, as Life Technologies, has a prime position in the next-generation sequencing market, while Thermo Electron added a huge healthcare customer base with the Fisher acquisition of 2006 and, last month, bought biomarker expert BRAHMS. Of course, there are the players from the medtech field, such as Siemens Healthcare, which made three big diagnostics investments in DPC, Bayer’s diagnostics business and Dade-Behring. Even an established diagnostics company like Beckman Coulter continues to buy in new assets and expand its geographical reach, such as with the Olympus diagnostics unit.
You may also be interested in...
The market for biomarkers in neurological diseases is an increasingly attractive one for many diagnostics companies. An improved understanding of the disorders and the possibility of disease-modifying drugs could lead to the discovery of more diagnostic markers and, hopefully, earlier diagnosis. In neurodegenerative illnesses, earlier intervention could stave off further loss of neurological function. This in turn would improve a patient's quality of life, and reduce the economic burden on society.
For anyone following the fastest-growing companies in the companion diagnostics sector, last month’s acquisition of DxS by Qiagen for up to $130m was no surprise. Qiagen has had its eye on personalised healthcare for quite a while now, and DxS is a very promising addition to the Venlo-based company.
Last week the biopharmaceutical industry rejoiced when the US Patent and Trademark Office (USPTO), under its new head David Kappos, dropped its proposed patent rules limiting the number of times additional claims could be filed, which were designed to reduce the growing backlog of unexamined filings (see scripnews.com, October 12, 2009).